GlassScriptPhysician profile
Richard B Dewey
NPI 1992890974
$95,762.78
in general payments reported to CMS, 2019-2025
16 companies · $853 in 2025
The $853 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $25K · 2020: $19K · 2021: $3,638 · 2022: $23K · 2023: $5,145 · 2024: $19K · 2025: $853.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $18K · Consulting Fee: $4,100 · Food and Beverage: $2,408.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $18,238.50 |
| Consulting Fee | $4,100.00 |
| Food and Beverage | $2,408.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amneal Pharmaceuticals LLC | $66,787.21 | 2019-2025 | Rytary, Crexont, Ongentys |
| Abbott Laboratories | $20,227.92 | 2022-2025 | Infinity |
| Merz Pharmaceuticals, LLC | $4,173.08 | 2022-2025 | Xeomin, Inbrija |
| Acorda Therapeutics, INC | $2,960.17 | 2020-2023 | Inbrija |
| Neurocrine Biosciences, INC. | $505.91 | 2022-2025 | Ingrezza, Ongentys |
| Abbvie INC. | $397.81 | 2019-2025 | Duopa |
| Kyowa Kirin, INC. | $253.92 | 2023 | Nourianz |
| Boston Scientific Corporation | $96.73 | 2019 | |
| Medtronic USA, INC. | $74.09 | 2019 | |
| Mdd US Operations, LLC | $65.94 | 2019-2023 | Apokyn |
| Acadia Pharmaceuticals INC | $60.69 | 2023-2025 | Nuplazid |
| Lilly USA, LLC | $45.18 | 2023-2024 | Amyvid, Kisunla |
| Eisai INC. | $42.94 | 2024-2025 | |
| Cala Health, INC. | $28.96 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $25.62 | 2023 | Rexulti |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Revance Therapeutics, INC. | $16.61 | 2025 | Daxxify |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Dewey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.